Legend Biotech Corp (LEGN)
45.41
-0.52
(-1.13%)
USD |
NASDAQ |
May 03, 16:00
45.42
0.00 (0.00%)
After-Hours: 20:00
Legend Biotech Cash from Operations (TTM): -393.28M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -393.28M |
September 30, 2023 | -347.37M |
June 30, 2023 | -358.64M |
March 31, 2023 | -263.65M |
December 31, 2022 | -201.28M |
September 30, 2022 | -221.09M |
June 30, 2022 | -193.57M |
March 31, 2022 | -250.36M |
December 31, 2021 | -198.46M |
Date | Value |
---|---|
September 30, 2021 | -184.87M |
June 30, 2021 | -204.65M |
March 31, 2021 | -204.00M |
December 31, 2020 | -223.00M |
September 30, 2020 | -227.04M |
June 30, 2020 | -142.72M |
March 31, 2020 | -124.60M |
December 31, 2019 | -83.06M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-393.28M
Minimum
Dec 2023
-83.06M
Maximum
Dec 2019
-224.80M
Average
-204.65M
Median
Jun 2021
Cash from Operations (TTM) Benchmarks
Johnson & Johnson | 23.19B |
Bristol-Myers Squibb Co | 13.72B |
2seventy bio Inc | -166.86M |
Exelixis Inc | 317.74M |
Alnylam Pharmaceuticals Inc | 189.12M |